Immunovant (IMVT) Assets Average (2019 - 2026)

Immunovant has reported Assets Average for 8 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 67.85% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 67.85% YoY), and the FY2026 full-year result was $866.6 million, up 20.15% from the prior year.
• Assets Average for Q1 2026 stood at $1.0 billion, up from $817.7 million in the prior quarter.
• The five-year high for Assets Average was $1.0 billion in Q1 2026, with the low at $321.6 million in Q3 2023.
• Historically, Assets Average has averaged $566.8 million across 5 years, with a median of $529.4 million in 2022.
• Annual changes were most pronounced in 2023 — Assets Average fell 27.46% — and 2025, when it soared 74.6%.
• Immunovant's Assets Average stood at $442.2 million in 2022, then grew by 13.47% to $501.8 million in 2023, then fell by 6.66% to $468.3 million in 2024, then soared by 74.6% to $817.7 million in 2025, then increased by 22.87% to $1.0 billion in 2026.
• The last three Assets Average figures came in at $1.0 billion (Q1 2026), $817.7 million (Q4 2025), and $622.2 million (Q3 2025), per Business Quant data.